Controlled randomized crossover of essential oils for quality of life in children with autism spectrum disorder (ASD): A pilot and feasibility study / Xueliang PAN ; Taylor WONG ; Craig WILLIAMS ; Cheryl JAMES ; L. Eugene ARNOLD in Research in Autism, 125 (July 2025)  

Public ISBD [article]  inResearch in Autism > 125 (July 2025) . - p.202603 Titre : Controlled randomized crossover of essential oils for quality of life in children with autism spectrum disorder (ASD): A pilot and feasibility study Type de document : Texte imprimé et/ou numérique Auteurs : Xueliang PAN, Auteur ; Taylor WONG, Auteur ; Craig WILLIAMS, Auteur ; Cheryl JAMES, Auteur ; L. Eugene ARNOLD, Auteur Article en page(s) : p.202603 Langues : Anglais (eng) Mots-clés : Essential oils  Autism spectrum disorder  Feasibility study  Quality of life  Sleep  Anxiety  Proinflammatory cytokines Index. décimale : PER Périodiques Résumé : Introduction Essential oils have been touted to benefit children with autism spectrum disorder (ASD) in a multitude of ways. However, the lack of empirical evidence makes it difficult to accept this claim. We tested the feasibility of conducting a large randomized clinical crossover trial of an essential oils blend in children with ASD and evaluated its safety and efficacy for improving quality of life. Methods Children ages 3-9 with ASD were randomized to a crossover study of Reconnect?, an essential oils blend, versus a control. Outcomes were the Pediatric Quality of Life Inventory, Parent-Rated Anxiety Scale for ASD, Children?s Sleep Habits Questionnaire, and laboratory safety tests. Inflammatory cytokines and other labs were explored. Mixed-effects analyses were applied. Results Twenty-six participants evaluated as intent-to-treat population. Seventeen completed both conditions (61 %). Outcomes improved, but between-treatment differences in the crossover were nonsignificant (p = .33-.16). At first treatment endpoint, anxiety decreased significantly more with active than control (p = .015, d=1.01). Adverse events and hematological/hepatic/renal tests revealed no significant differences. C-reactive protein and interleukin-6 (IL-6) revealed no inflammation. Conclusion Recruitment was feasible, adherence was high, first-condition retention was high (92.7 %). Retention in second condition was low (65.4 %). A large crossover is not feasible. Anxiety results suggest further study in a randomized controlled trial with a parallel-groups design. Reconnect? appears safe. En ligne : https://doi.org/10.1016/j.reia.2025.202603 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=559 [article] Controlled randomized crossover of essential oils for quality of life in children with autism spectrum disorder (ASD): A pilot and feasibility study [Texte imprimé et/ou numérique] / Xueliang PAN, Auteur ; Taylor WONG, Auteur ; Craig WILLIAMS, Auteur ; Cheryl JAMES, Auteur ; L. Eugene ARNOLD, Auteur . - p.202603. Langues : Anglais (eng) in Research in Autism > 125 (July 2025) . - p.202603 Mots-clés : Essential oils  Autism spectrum disorder  Feasibility study  Quality of life  Sleep  Anxiety  Proinflammatory cytokines Index. décimale : PER Périodiques Résumé : Introduction Essential oils have been touted to benefit children with autism spectrum disorder (ASD) in a multitude of ways. However, the lack of empirical evidence makes it difficult to accept this claim. We tested the feasibility of conducting a large randomized clinical crossover trial of an essential oils blend in children with ASD and evaluated its safety and efficacy for improving quality of life. Methods Children ages 3-9 with ASD were randomized to a crossover study of Reconnect?, an essential oils blend, versus a control. Outcomes were the Pediatric Quality of Life Inventory, Parent-Rated Anxiety Scale for ASD, Children?s Sleep Habits Questionnaire, and laboratory safety tests. Inflammatory cytokines and other labs were explored. Mixed-effects analyses were applied. Results Twenty-six participants evaluated as intent-to-treat population. Seventeen completed both conditions (61 %). Outcomes improved, but between-treatment differences in the crossover were nonsignificant (p = .33-.16). At first treatment endpoint, anxiety decreased significantly more with active than control (p = .015, d=1.01). Adverse events and hematological/hepatic/renal tests revealed no significant differences. C-reactive protein and interleukin-6 (IL-6) revealed no inflammation. Conclusion Recruitment was feasible, adherence was high, first-condition retention was high (92.7 %). Retention in second condition was low (65.4 %). A large crossover is not feasible. Anxiety results suggest further study in a randomized controlled trial with a parallel-groups design. Reconnect? appears safe. En ligne : https://doi.org/10.1016/j.reia.2025.202603 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=559

A multisite trial of atomoxetine and parent training in children with autism spectrum disorders: Rationale and design challenges / Laura SILVERMAN in Research in Autism Spectrum Disorders, 8-7 (July 2014)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 8-7 (July 2014) . - p.899-907 Titre : A multisite trial of atomoxetine and parent training in children with autism spectrum disorders: Rationale and design challenges Type de document : Texte imprimé et/ou numérique Auteurs : Laura SILVERMAN, Auteur ; Jill A. HOLLWAY, Auteur ; Tristram SMITH, Auteur ; Michael G. AMAN, Auteur ; L. Eugene ARNOLD, Auteur ; Xueliang PAN, Auteur ; Xiaobai LI, Auteur ; Benjamin L. HANDEN, Auteur Article en page(s) : p.899-907 Langues : Anglais (eng) Mots-clés : Atomoxetine (Strattera)  ADHD  Autism spectrum disorder  Drug trial  Parent training Index. décimale : PER Périodiques Résumé : Abstract Several randomized controlled trials (RCTs) involving children with autism spectrum disorder (ASD) have examined effectiveness of mono-therapies for problem behavior. However, results have not been as encouraging as in typically developing children. For example, when prescribed stimulants, children with ASD and hyperactivity/inattentiveness, show only moderately reduced symptoms, with frequent side effects. Therefore, alternative treatments or combinations of treatments are needed. The Children's Hyperactivity and Autism Research Treatment Study (CHARTS) is a randomized clinical trial comparing the individual and combined effects of atomoxetine and parent training to treat hyperactivity, inattentiveness, and noncompliance in children with ASD. Design challenges included the overall study design, targeting of different outcomes by different treatments, and data analysis. This article details options for addressing a number of these methodological issues in the context of conducting a large multicenter RCT with an ASD population. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.03.013 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=233 [article] A multisite trial of atomoxetine and parent training in children with autism spectrum disorders: Rationale and design challenges [Texte imprimé et/ou numérique] / Laura SILVERMAN, Auteur ; Jill A. HOLLWAY, Auteur ; Tristram SMITH, Auteur ; Michael G. AMAN, Auteur ; L. Eugene ARNOLD, Auteur ; Xueliang PAN, Auteur ; Xiaobai LI, Auteur ; Benjamin L. HANDEN, Auteur . - p.899-907. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 8-7 (July 2014) . - p.899-907 Mots-clés : Atomoxetine (Strattera)  ADHD  Autism spectrum disorder  Drug trial  Parent training Index. décimale : PER Périodiques Résumé : Abstract Several randomized controlled trials (RCTs) involving children with autism spectrum disorder (ASD) have examined effectiveness of mono-therapies for problem behavior. However, results have not been as encouraging as in typically developing children. For example, when prescribed stimulants, children with ASD and hyperactivity/inattentiveness, show only moderately reduced symptoms, with frequent side effects. Therefore, alternative treatments or combinations of treatments are needed. The Children's Hyperactivity and Autism Research Treatment Study (CHARTS) is a randomized clinical trial comparing the individual and combined effects of atomoxetine and parent training to treat hyperactivity, inattentiveness, and noncompliance in children with ASD. Design challenges included the overall study design, targeting of different outcomes by different treatments, and data analysis. This article details options for addressing a number of these methodological issues in the context of conducting a large multicenter RCT with an ASD population. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.03.013 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=233

---

1 (1 - 2 / 2)